Patent · US Active

Anti-TLR4 antibodies and uses thereof

US10400044B2 · kind B2 · utility

1Cited by

1References

17Claims

0Family size

Assignee

Novimmune SA · CH

Inventors

Francois Rousseau · Gif-sur-Yvette, FR
Jeremy Loyau · Annemasse, FR
Nicolas Fischer · Geneva, CH
Greg Elson · Saint-Julien-en-Genevois, FR
Marie Kosco-Vilbois · Saint-Julien-en-Genevois, FR

Key dates

Filing date	Sep 26, 2016
Grant date	Sep 3, 2019
Priority date	—
Expiry date	Sep 26, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.